Neurocrine (NBIX) Shares Plunge as Data on NBI-98854 Fails to Hit Primary Endpoint
Tweet Send to a FriendGet Alerts NBIX Hot Sheet
Up)
Trade NBIX Now!
Neurocrine Biosciences (Nasdaq: NBIX) shares have fallen more than 11 percent after data from a Phase II study of VMAT2 inhibitor NBI-98854 for tardive dyskinesia did not meet the primary endpoint.
The stock last traded at $7.88. Shares closed at $8.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The stock last traded at $7.88. Shares closed at $8.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
- Tableau Software (DATA) IPO Surges Higher
- Herbalife (HLF) Active on Chatter
Create E-mail Alert Related Categories
Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
